I-Mab

Yahoo Finance • 15 days ago

Which stocks are gapping on Wednesday?

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT MWYN [https://www.chartmill.com/stock/... Full story

Yahoo Finance • 17 days ago

I-Mab to accelerate investment in givastomig

[Cancer cells vis] koto_feja/E+ via Getty Images I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) said on Monday that it is accelerating investment in its lead drug candidate, givastomig, a bispecific antibody for cancer treatme... Full story

Yahoo Finance • last month

Form 6K I Mab For: 25 August

... Full story

Yahoo Finance • last month

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced tha... Full story

Yahoo Finance • last month

I-Mab Biopharma GAAP EPS of -$0.07 misses by $0.02

* I-Mab Biopharma press release [https://seekingalpha.com/pr/20206192-i-mab-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]): Q2 GAAP EPS of -$0.07 misses by... Full story

Yahoo Finance • last month

I-Mab completes enrollment for givastomig trial ahead of schedule

ROCKVILLE, Md. - I-Mab (NASDAQ:IMAB), a clinical-stage biopharmaceutical company with a market capitalization of $392 million, announced Monday that enrollment in the Phase 1b dose expansion cohorts for its bispecific antibody givastomig h... Full story

Yahoo Finance • 2 months ago

Unusual volume stocks are being observed in Wednesday's session.

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT TNON [https://www.chartmill.com/stock/quote/TNON/profile] 7.14% The... Full story

Yahoo Finance • 2 months ago

The trading volume of these stocks is deviating from the norm in today's session.

Which stocks have an unusual volume on Tuesday? [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SVIIR [https://www.chartmill.com/stock/quote/SVIIR/profile] 1.82% 295.38K shares of SPRING VALLEY ACQUISI... Full story

Yahoo Finance • 2 months ago

Unusual volume stocks in Monday's session

Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:P... Full story

Yahoo Finance • 2 months ago

I-Mab to buy Bridge Health Biotech

[Magnifying glass and documents with analytics data lying on tabl] tonefotografia/iStock via Getty Images I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) said on Thursday that it has signed an agreement to acquire Bridge Health... Full story

Yahoo Finance • 2 months ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge H... Full story

Yahoo Finance • 2 months ago

I-Mab to Present at the BTIG Virtual Biotechnology Conference

ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced tha... Full story

Yahoo Finance • 3 months ago

I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointe... Full story

Yahoo Finance • 3 months ago

I-Mab reports 83% response rate for givastomig in gastric cancer study

ROCKVILLE - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company currently valued at $188 million, announced positive Phase 1b data for its bispecific antibody givastomig in combination with nivolumab and mFOLFOX6 for gastric cancer treat... Full story

Yahoo Finance • 3 months ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host i... Full story

Yahoo Finance • 3 months ago

I-Mab's givastomig shows promising results in gastric cancer study

ROCKVILLE, MD - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company whose stock has surged over 200% in the past six months, announced Monday that data from its first-in-human study of givastomig, a bispecific antibody targeting Claudin... Full story

Yahoo Finance • 3 months ago

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-b... Full story

Yahoo Finance • 3 months ago

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 e... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data

Investing.com - H.C. Wainwright maintained its buy rating and $7.00 price target on I-Mab (NASDAQ:IMAB) stock Tuesday as the company prepares to present Phase 1b data for its cancer drug givastomig at the ESMO GI conference on July 2, 2025... Full story

Yahoo Finance • 3 months ago

I-Mab regains compliance with Nasdaq’s listing rule

* I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) has regained compliance [https://seekingalpha.com/pr/20134567-i-mab-regains-compliance-with-nasdaq-minimum-bid-price-requirement]with Nasdaq’s $1.00 minimum bid price listing r... Full story